This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -166.67% and 1.14%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
Varian's (VAR) Halcyon to Treat Patients at Japan's Hospital
by Zacks Equity Research
Varian's (VAR) Halcyon sees encouraging developments in recent times.
Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise
by Zacks Equity Research
Solid demand for Accuray's (ARAY) Radixact, CyberKnife and TomoTherapy platforms continue to boost business.
Accuray (ARAY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 75.00% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
Management at Accuray (ARAY) sees significant opportunities in China.
Varian Medical's (VAR) ProBeam Installed in China's HIMC
by Zacks Equity Research
Varian Medical (VAR) has seen some notable developments in its Proton Therapy business in recent times.
AngioDynamics' Latest FDA Approval to Boost Oncology Unit
by Zacks Equity Research
AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.
Varian Medical (VAR) Collaborates With Korea-Based Hospital
by Zacks Equity Research
Varian Medical (VAR) has seen notable developments in Asia of late.
Intuitive Surgical da Vinci SP Gets FDA Nod, Prospects Bright
by Zacks Equity Research
Intuitive Surgical (ISRG) fortifies its foothold in the global robotic-surgery market.
Varian & Tata Trust Tie Up to Boost Radiotherapy in India
by Zacks Equity Research
Varian's (VAR) three-year deal with Tata Trust is likely to fortify its foothold in the Asia-Pacific radiotherapy space.
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.
Varian Strong on Global Expansion and Proton Therapy Arm
by Zacks Equity Research
Varian's (VAR) strong presence in China instills optimism in the stock.
Accuray & China Isotope Collaborate to Sell Radiation Devices
by Zacks Equity Research
Management at Accuray (ARAY) sees bright prospects in China.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
Will Accuray (ARAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
Why Is Accuray (ARAY) Down 6.7% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are WMGI & ARAY Neck and Neck? Let's Take a Closer Look
by Zacks Equity Research
Wright Medical (WMGI) scores higher than Accuray (ARAY) when it comes to current-year earnings and growth projections.
Accuray (ARAY) Q1 Loss Wider Than Expected, Gross Orders Rise
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q1 results; strong EBITDA guidance instils hope.
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -16.67% and 0.77%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Q1 Earnings Preview: What to Look Out For
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.